Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines Update; Webinar, 79183-79184 [2020-26974]

Download as PDF jbell on DSKJLSW7X2PROD with NOTICES Federal Register / Vol. 85, No. 237 / Wednesday, December 9, 2020 / Notices the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees. The FCC may not conduct or sponsor a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the PRA that does not display a valid OMB control number. DATES: Written PRA comments should be submitted on or before February 8, 2021. If you anticipate that you will be submitting comments but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible. ADDRESSES: Direct all PRA comments to Cathy Williams, FCC, via email to PRA@ fcc.gov and to Cathy.Williams@fcc.gov. FOR FURTHER INFORMATION CONTACT: For additional information about the information collection, contact Cathy Williams at (202) 418–2918. SUPPLEMENTARY INFORMATION: OMB Control Number: 3060–1030. Title: Service Rules for Advanced Wireless Services (AWS) in the 1.7 GHz and 2.1 GHz Bands. Form Number: N/A. Type of Review: Extension of a currently approved collection. Respondents: Business or other forprofit entities; state, local, or tribal government; Federal Government and not for profit institutions. Number of Respondents: 232 Respondents; 6,812 responses. Estimated Time per Response: 0.25 to 5 hours. Frequency of Response: Annual, semiannual, one time, and on occasion reporting requirements, recordkeeping requirement, third-party disclosure requirements, and every ten years reporting requirements. Obligation to Respond: Required to obtain or retain benefits. The statutory authority for this collection is contained in sections 1, 2, 4(i), 201, 301, 302, 303, 307, 308, 309, 310, 316, 319, 324, 332, and 333 of the Communications Act of 1934, as amended, and sections 6003, 6004, and 6401 of the Middle Class Tax Relief Act of 2012, Public Law 112–96, 126 Stat. 156, 47 U.S.C. 151, 152, 154(i), 201, 301, 302(a), 303, 307, 308, 309, 310, 316, 319, 324, 332, 333, 1403, 1404, and 1451. Total Annual Burden: 13,866 hours. VerDate Sep<11>2014 16:16 Dec 08, 2020 Jkt 253001 79183 Total Annual Cost: $782,618. Privacy Impact Assessment: No impact(s). Nature and Extent of Confidentiality: There is no need for confidentiality with this collection of information. Needs and Uses: The currently approved information collections under Control No. 3060–1030 relate to three groups of Advanced Wireless Service (‘‘AWS’’) spectrum, commonly referred to as AWS–1, AWS–3, and AWS–4. The FCC’s policies and rules apply to application, licensing, operating and technical rules for this spectrum. The respondents are AWS licensees, incumbent Fixed Microwave Service (FS) and Broadband Radio Service (BRS) licensees that relocate out of the AWS bands, and AWS Clearinghouses that keep track of cost sharing obligations. AWS licensees also have coordination requirements with certain Federal Government incumbents. Recordkeeping, reporting, and thirdparty disclosure requirements associated with the FCC items listed in item 1 will be used by incumbent licensees and new entrants to negotiate relocation agreements and to coordinate operations to avoid interference. The information also will be used by the clearinghouses to maintain a national database, determine reimbursement obligations of entrants pursuant to the Commission’s rules, and notify such entrants of their reimbursement obligations. Additionally, the information will be used to facilitate dispute resolution and for FCC oversight of the clearinghouses and the costsharing plan. immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than December 23, 2020. A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. Trudy M. Durfee Revocable Trust, Trudy M. Durfee, as trustee, both of Sundance, Wyoming; to acquire voting shares of Sundance Bankshares, Inc., and thereby indirectly acquire voting shares of Sundance State Bank, both in Sundance, Wyoming. In addition, The Danny K. Hopson and Janice Dee Hopson Family Trust, Danny K. Hopson and Janice Dee Hopson, as co-trustees, all of San Tan Valley, Arizona; to become members of the Richard Durfee Family Group, a group acting in concert, and to retain voting shares of Sundance Bankshares, Inc., and indirectly retain voting shares of Sundance State Bank. Federal Communications Commission. Marlene Dortch, Secretary, Office of the Secretary. Board of Governors of the Federal Reserve System, December 3, 2020. Michele Taylor Fennell, Deputy Associate Secretary of the Board. [FR Doc. 2020–26983 Filed 12–8–20; 8:45 am] BILLING CODE 6712–01–P BILLING CODE P FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for PO 00000 Frm 00022 Fmt 4703 [FR Doc. 2020–26980 Filed 12–8–20; 8:45 am] Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines Update; Webinar Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of public webinar. AGENCY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and SUMMARY: E:\FR\FM\09DEN1.SGM 09DEN1 jbell on DSKJLSW7X2PROD with NOTICES 79184 Federal Register / Vol. 85, No. 237 / Wednesday, December 9, 2020 / Notices Human Services (HHS), announces a webinar entitled, ‘‘CDC STI Treatment Guidelines Update’’. The purpose of the webinar is for CDC to receive comments from potential users on the proposed updated guidelines. This webinar is an opportunity for all interested parties to ask questions and provide feedback, but is specifically directed toward clinicians, such as medical doctors, nurse practitioners, and physician’s assistants. CDC will consider comments made during the webinar prior to finalizing the updated STI Treatment Guidelines for publication. DATES: The webinar will be held on December 18, 2020 from 2 p.m. to 4 p.m. EST. Registration instructions can be found on the website, https:// www.cdc.gov/std/treatment/default.htm. ADDRESSES: The webinar will be broadcast from the Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, Georgia 30329. FOR FURTHER INFORMATION CONTACT: Quinn Haaga, Public Health Advisor, CDC, 1600 Clifton Road NE, MS–US 12– 2, Atlanta, GA 30329, stdtxguidelines@ cdc.gov. SUPPLEMENTARY INFORMATION: The CDC’s STI Treatment Guidelines Webinar is a public presentation of proposed updates to the CDC’s 2015 STD Treatment Guidelines. The webinar will include discussions of proposed changes to CDC’s 2015 STD Treatment Guidelines focusing on (1) changes to testing, management, and/or treatment recommendations for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis treatment; (2) role of metronidazole in pelvic inflammatory disease treatment; (3) alternative treatment options for bacterial vaginosis; (4) management of Mycoplasma genitalium; and (5) two step testing for serologic diagnosis of genital HSV2. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STIs. Comments and questions on the proposed changes may be made during the webinar only. Please refer to the posted agenda for updates about the webinar one week prior to the meeting. Information will be provided on the following website when it becomes available. https:// www.cdc.gov/std/treatment/default.htm. A recording of the webinar and accompanying transcripts will be available by January 17, 2021 on the website listed above. In addition, CDC’s responses to questions from the webinar will also be available February 15, 2021 on this website. Participants must register by December 17, 2020. This is a webinar- VerDate Sep<11>2014 16:16 Dec 08, 2020 Jkt 253001 only event and there will be no on-site participation at the CDC broadcast facility. Sandra Cashman, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2020–26974 Filed 12–8–20; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2020–0122] Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting and request for comment. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web. DATES: The meeting will be held on December 11, 2020 from 12:00 p.m. to 5:00 p.m. EST and December 13, 2020 from 12:00 p.m. to 4:00 p.m. EST (times subject to change, see the ACIP website for any updates: https://www.cdc.gov/ vaccines/acip/). Written comments must be received on or before December 14, 2020. ADDRESSES: For more information on ACIP please visit the ACIP website: https://www.cdc.gov/vaccines/acip/ index.html. You may submit comments, identified by Docket No. CDC–2020–0122 by any of the following methods: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Docket No. CDC–2020–0122, c/o Attn: December 11 and 13, 2020 ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24–8, Atlanta, GA 30329–4027. Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For SUMMARY: PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 access to the docket to read background documents or comments received, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS–H24–8, Atlanta, GA 30329– 4027; Telephone: 404–639–8367; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102–3.150(b), less than 15 calendar days’ notice is being given for this meeting due to the exceptional circumstances of the COVID–19 pandemic and rapidly evolving COVID–19 vaccine development and regulatory processes. The Secretary of Health and Human Services has determined that COVID–19 is a Public Health Emergency. A notice of this ACIP meeting has also been posted on CDC’s ACIP website at: https:// www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP. Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussions on COVID–19 vaccine. A recommendation vote(s) is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/ meetings/meetings-info.html. Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting E:\FR\FM\09DEN1.SGM 09DEN1

Agencies

[Federal Register Volume 85, Number 237 (Wednesday, December 9, 2020)]
[Notices]
[Pages 79183-79184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26974]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Centers for Disease Control and Prevention Sexually Transmitted 
Infection Treatment Guidelines Update; Webinar

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of public webinar.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), located 
within the Department of Health and

[[Page 79184]]

Human Services (HHS), announces a webinar entitled, ``CDC STI Treatment 
Guidelines Update''. The purpose of the webinar is for CDC to receive 
comments from potential users on the proposed updated guidelines. This 
webinar is an opportunity for all interested parties to ask questions 
and provide feedback, but is specifically directed toward clinicians, 
such as medical doctors, nurse practitioners, and physician's 
assistants. CDC will consider comments made during the webinar prior to 
finalizing the updated STI Treatment Guidelines for publication.

DATES: The webinar will be held on December 18, 2020 from 2 p.m. to 4 
p.m. EST. Registration instructions can be found on the website, 
https://www.cdc.gov/std/treatment/default.htm.

ADDRESSES: The webinar will be broadcast from the Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Atlanta, Georgia 30329.

FOR FURTHER INFORMATION CONTACT: Quinn Haaga, Public Health Advisor, 
CDC, 1600 Clifton Road NE, MS-US 12-2, Atlanta, GA 30329, 
[email protected].

SUPPLEMENTARY INFORMATION: The CDC's STI Treatment Guidelines Webinar 
is a public presentation of proposed updates to the CDC's 2015 STD 
Treatment Guidelines. The webinar will include discussions of proposed 
changes to CDC's 2015 STD Treatment Guidelines focusing on (1) changes 
to testing, management, and/or treatment recommendations for Neisseria 
gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis treatment; 
(2) role of metronidazole in pelvic inflammatory disease treatment; (3) 
alternative treatment options for bacterial vaginosis; (4) management 
of Mycoplasma genitalium; and (5) two step testing for serologic 
diagnosis of genital HSV2. Physicians and other health-care providers 
can use these guidelines to assist in the prevention and treatment of 
STIs. Comments and questions on the proposed changes may be made during 
the webinar only.
    Please refer to the posted agenda for updates about the webinar one 
week prior to the meeting. Information will be provided on the 
following website when it becomes available. https://www.cdc.gov/std/treatment/default.htm. A recording of the webinar and accompanying 
transcripts will be available by January 17, 2021 on the website listed 
above. In addition, CDC's responses to questions from the webinar will 
also be available February 15, 2021 on this website.
    Participants must register by December 17, 2020. This is a webinar-
only event and there will be no on-site participation at the CDC 
broadcast facility.

Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2020-26974 Filed 12-8-20; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.